Sunitinib and Atrial Trabeculae Contractility (SCAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01246778|
Recruitment Status : Completed
First Posted : November 23, 2010
Last Update Posted : May 1, 2014
Recently, sunitinib (a tyrosine kinase inhibitor that is used for treatment of metastatic renal carcinoma and gastrointestinal stroma tumors) has been associated with development of heart failure, possibly by off-target inhibition of AMP-protein kinase. The investigators hypothesize that sunitinib reduces the contractile ability of myocardium and the tolerance against ischemia-reperfusion and that activators of AMP-protein kinase such as atorvastatin and AICAR reverse this unwanted effect of sunitinib.
The primary objective of the study is to investigate the effect of sunitinib on ex-vivo atrial contractile force in absence and presence of ischemia-reperfusion.
A secondary objective is to explore if atorvastatin or AICAR prevent sunitinib-induced deterioration of contractile function of human atrial trabeculas. Study design: Lab
|Condition or disease|
|Cardiotoxicity Ischemia Heart Failure|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||The Influence of Sunitinib on Contractility of Human Atrial Trabeculae|
|Study Start Date :||November 2010|
|Primary Completion Date :||April 2014|
|Study Completion Date :||April 2014|
Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
With/without sunitinib IP
Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
- Force [ Time Frame: 200 minutes ]The developed force in ex vivo atrial trabeculae during standardized stimulation.
- Speed [ Time Frame: 200 minutes ]The difference in averaged maximal speed of tension reduction during relaxation between two trabeculae
- Maximal Speed [ Time Frame: 210 minutes ]The difference in averaged maximal speed of tension development during contraction between two trabeculae.
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01246778
|Radboud University Nijmegen Medical Centre|
|Nijmegen, Netherlands, 6500HB|
|Principal Investigator:||G. A. Rongen||Radboud University|